Recent Updates
Recently added Catalysts

GSK3888550A RSV Maternal vaccine formulation 1

Phase 1

Respiratory Syncytial Virus Infections | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Aug 13, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment502

FDA Designations

No designations recorded

Clinical trial landscape

GSK3888550A RSV Maternal vaccine formulation 1 · 1 trial · 1 indication

Phase 1 1
NCT03674177A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant WomenRespiratory Syncytial Virus Infections
COMPLETED502 Analytics
PHASE1COMPLETED
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
Respiratory Syncytial Virus InfectionsUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Subjects With Any and Grade 3 Solicited Local Adverse Events (AE) During a 7-day Follow-up Period
During a 7-day follow-up period (i.e., on the day of vaccination and 6 subsequent days)

Assessed solicited local symptoms include pain, redness and swelling, at the injection site. Any = occurrence of the AE regardless of intensity grade. Any Redness and swelling symptom = symptom reported with a surface diameter greater than 20 millimeters. Grade 3 pain = significant pain at rest, pain that prevented normal every day activity. Grade 3 redness/swelling = symptom reported with a surface diameter greater than 100 millimeters.

Number of Subjects With Any, Grade 3 and Related Solicited General Adverse Events (AE) During a 7-day Follow-up Period
During a 7-day follow-up period (i.e., on the day of vaccination and 6 subsequent days)

Assessed solicited general symptoms include fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhea and/or abdominal pain), headache and fever. Any Fatigue, gastrointestinal symptoms and headache = occurrence of the symptom regardless of intensity grade and relationship. Any Fever = temperature higher than or equal to 38.0 degrees Celsius (°C), or 100.4 degrees Fahrenheit (°F). Grade 3 Fatigue, gastrointestinal symptoms and headache = symptoms that prevented normal activities. Grade 3 Fever = temperature higher than 39.0 degrees Celsius (°C), or 102.2 degrees Fahrenheit (°F). Related fatigue, gastrointestinal symptoms, headache and fever(\>38°C) = symptoms assessed by the investigator as related to the vaccination.

Number of Subjects With Any Unsolicited AEs During a 30-day Follow-up Period
During a 30-day follow-up period after vaccination (i.e., on the day of vaccination and 29 subsequent days)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Number of Subjects With Serious Adverse Events (SAEs) During a 30-day Follow-up Period
From Day 1 (vaccination) up to Day 30 (i.e., on the day of vaccination and 29 subsequent days)

Assessed SAEs include any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, or results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject.

Number of Subjects With Hematological Laboratory Results Change With Respect to Normal Laboratory Ranges and Versus Baseline, at Day 8
At Day 8

Assessed hematological laboratory parameters include Eosinophils, Hemoglobin, Lymphocytes, Neutrophils, Platelets, White blood cells (WBC). Hematological abnormalities refer to range indicator at timing, categorized as BELOW, WITHIN or ABOVE normal ranges, and compared to baseline range indicator i.e. BELOW(SCR), WITHIN(SCR) or ABOVE(SCR). \[e.g. WBC, BELOW(SCR), BELOW = WBC BELOW normal ranges at baseline versus BELOW normal ranges at Day 8\].

Number of Subjects With Hematological Laboratory Results Change With Respect to Normal Laboratory Ranges and Versus Baseline, at Day 31
At Day 31

Assessed hematological laboratory parameters include Eosinophils, Hemoglobin, Lymphocytes, Neutrophils, Platelets, White blood cells (WBC). Hematological abnormalities refer to range indicator at timing, categorized as BELOW, WITHIN or ABOVE normal ranges, and compared to baseline range indicator i.e. BELOW(SCR), WITHIN(SCR) or ABOVE(SCR) \[e.g. WBC, BELOW(SCR), BELOW = WBC BELOW normal ranges at baseline versus BELOW normal ranges at Day 31\].

Number of Subjects With Biochemical Laboratory Results Change With Respect to Normal Laboratory Ranges and Versus Baseline, at Day 8
At Day 8

Assessed biochemical laboratory parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine. Biochemical abnormalities refer to range indicator at timing, categorized as BELOW, WITHIN or ABOVE normal ranges, and compared to baseline range indicator i.e. BELOW(SCR), WITHIN(SCR) or ABOVE(SCR)\[e.g. ALT, BELOW(SCR), BELOW = ALT BELOW normal ranges at baseline versus BELOW normal ranges at Day 8\].

Number of Subjects With Biochemical Laboratory Results Change With Respect to Normal Laboratory Ranges and Versus Baseline, at Day 31
At Day 31

Assessed biochemical laboratory parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine and blood urea nitrogen (BUN). Biochemical abnormalities refer to range indicator at timing, categorized as BELOW, WITHIN or ABOVE normal ranges, and compared to baseline range indicator i.e. BELOW(SCR), WITHIN(SCR) or ABOVE(SCR) \[e.g. ALT, BELOW(SCR), BELOW = ALT BELOW normal ranges at baseline versus BELOW normal ranges at Day 31\].

Number of Subjects With Hematological Laboratory Results Versus Baseline, by Maximum Grading, at Day 8
At Day 8

Assessed hematological laboratory parameters include Eosinophils, Hemoglobin, Lymphocytes Decrease, Neutrophils Decrease, Platelets Decrease, WBC Decrease and WBC Increase, as graded by the Food and Drug Administration \[FDA\] Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Assessed grades at specified time point, are Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life threatening, as compared to the baseline status of the same parameter, at baseline \[e.g. WBC decrease-Grade 1(SCR)-Grade 1 = WBC decrease Grade 1 at baseline versus Grade 1 at Day 8\]. "Any" corresponding to any grade and "Grade 0" to normal ranges.

Number of Subjects With Hematological Laboratory Results Versus Baseline, by Maximum Grading, at Day 31
At Day 31

Assessed hematological laboratory parameters include Eosinophils, Hemoglobin, Lymphocytes Decrease, Neutrophils Decrease, Platelets Decrease, WBC Decrease and WBC Increase, as graded by the Food and Drug Administration \[FDA\] Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Assessed grades at specified time point, are Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life threatening, as compared to the baseline status of the same parameter, at baseline \[e.g. WBC decrease-Grade 1(SCR)-Grade 1 = WBC decrease Grade 1 at baseline versus Grade 1 at Day 31\]. "Any" corresponding to any grade and "Grade 0" to normal ranges.

Number of Subjects With Biochemical Laboratory Results Versus Baseline, by Maximum Grading, at Day 8
At Day 8

Assessed biochemical laboratory parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine, as graded by the Food and Drug Administration \[FDA\] Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Assessed grades at specified time point, are Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life threatening, as compared to the baseline status of the same parameter, at baseline \[e.g. ALT-Grade 1(SCR)-Grade 1 = ALT Grade 1 at baseline versus Grade 1 at Day 8\]. "Any" corresponding to any grade and "Grade 0" to normal ranges.

Number of Subjects With Biochemical Laboratory Results Versus Baseline, by Maximum Grading, at Day 31
At Day 31

Assessed biochemical laboratory parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine, as graded by the Food and Drug Administration \[FDA\] Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Assessed grades at specified time point, are Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life threatening, as compared to the baseline status of the same parameter, at baseline \[e.g. ALT-Grade 1(SCR)-Grade 1 = ALT Grade 1 at baseline versus Grade 1 at Day 31\]. "Any" corresponding to any grade and "Grade 0" to normal ranges.

Secondary Endpoints

Number of Subjects With SAEs
From Day 1 (vaccination) up to Day 91 and up to Day 181
Neutralizing Antibody (Nab) Titers Against RSV Serotype A
At pre-vaccination at screening (PRE), 7 days post vaccination (Day 8), 30 days post vaccination (Day 31), 60 days post vaccination (Day 61) and 90 days post vaccination (Day 91)
Anti-RSVPreF3 Immunoglobulin G (IgG) Antibody Concentrations
At pre-vaccination at screening (PRE), 7 days post vaccination (Day 8), 30 days post vaccination (Day 31), 60 days post vaccination (Day 61) and 90 days post vaccination (Day 91)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
RSV MAT formulation 1 GroupEXPERIMENTALSubjects received a single dose (30 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
RSV MAT formulation 2 GroupEXPERIMENTALSubjects received a single dose (60 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
RSV MAT formulation 3 GroupEXPERIMENTALSubjects received a single dose (120 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
Control GroupPLACEBO_COMPARATORSubjects received a single placebo saline injection at Day 1, intramuscularly into the deltoid region of the non-dominant arm

Interventions

NameTypeDescription
GSK3888550A RSV Maternal vaccine formulation 1BIOLOGICALSingle dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
GSK3888550A RSV Maternal vaccine formulation 2BIOLOGICALSingle dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
GSK3888550A RSV Maternal vaccine formulation 3BIOLOGICALSingle dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
Placebo (Normal Saline)DRUGSingle dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexFEMALE
Healthy VolunteersYes
Study Sites11

Inclusion Criteria: * Subjects who the investigator believes will comply with the requirements of the protocol (e.g. completion of the diary cards/questionnaires, return for follow-up visits, have regular contact to allow evaluation during the study); * Written informed consent obtained from the su...

Countries:United StatesFinlandGermany
Unlock Eligibility Criteria

Frequently asked questions about GSK3888550A RSV Maternal vaccine formulation 1

What is GSK3888550A used for?

GSK3888550A is an investigational vaccine being developed for Respiratory Syncytial Virus (RSV) infections. It is designed to be given to healthy non-pregnant women to evaluate the safety and the antibodies produced following vaccine administration. The vaccine is currently in Phase 1 clinical development.

Who makes GSK3888550A?

GSK3888550A is being developed by GSK plc, a biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in healthy non-pregnant women.

What phase is GSK3888550A in?

GSK3888550A is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed to evaluate the vaccine's safety and the antibodies produced following administration.

What clinical trials is GSK3888550A in?

GSK3888550A has one completed clinical trial registered as NCT03674177. This Phase 1 study evaluated different dose levels of the vaccine in healthy non-pregnant women aged 18 years and older. The trial enrolled 502 participants across the United States, Finland, and Germany.

Is GSK3888550A a monoclonal antibody?

GSK3888550A is described as a monoclonal antibody modality, but it is being studied as an investigational vaccine for Respiratory Syncytial Virus infections. The Phase 1 trial evaluates the vaccine's safety and the antibodies produced following administration in healthy non-pregnant women.